Evidence map›Paper›PMID 23928392›Full record

ReviewAdvances in chronic kidney disease2013

New developments in the pathogenesis of preeclampsia.

Mihran V Naljayan, S Ananth Karumanchi

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Advances in chronic kidney disease, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02351583 (Microcirculatory and Tissue and Cerebral Oxygenation Differences Between Preeclampsia and Normal Pregnancy), which is not on this map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
9.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02351583 withdrawnnot on this mapstarted 2015, after this paper: background citation

Microcirculatory and Tissue and Cerebral Oxygenation Differences Between Preeclampsia and Normal Pregnancy: An Observation Study

TypeobservationalSponsorUniversity of VirginiaRan2015 to 2017Enrolled0ConditionsPregnancy, EclampsiaArmsCytoCam, NIRS Artinis PortaLite with OxySoft softwear
3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. An evaluation of calprotectin as serum marker of preeclampsia: a systematic review of observational studies.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2016
    Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Is Atrial Natriuretic Peptide (ANP) and Natriuretic Peptide Receptor-A (NPR-A) Expression in Human Placenta and Decidua Normal?Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Mihran V NaljayanRenal, Molecular, and Vascular Medicine Divisions, Department of Medicine, Beth Israel-Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
S Ananth Karumanchi
Harvard University · USHoward Hughes Medical Institute · US

Funding

Howard Hughes Medical Institute
6 · The paper itself

Abstract

Preeclampsia affects 3% to 5% of all pregnancies and is a major cause of maternal and perinatal morbidity and mortality worldwide. This disorder is characterized by a constellation of signs and symptoms, most notably new-onset hypertension and proteinuria during the last trimester of pregnancy. In this review, the molecular mechanisms of preeclampsia with an emphasis on the role of circulating antiangiogenic proteins in the pathogenesis of preeclampsia and its complications will be discussed.

Indexed as

Angiogenesis InhibitorsAntigens, CDEndoglinFemaleHumansPlacentaPre-EclampsiaPregnancyReceptors, Cell SurfaceVascular Endothelial Growth Factor Receptor-1Angiogenesis InhibitorsAntigens, CDEndoglinENG protein, humanFLT1 protein, humanReceptors, Cell SurfaceVascular Endothelial Growth Factor Receptor-1

Identifiers

PMID23928392
PMCPMC4107338
OpenAlexW1963481251

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.